ClinicalTrials.gg
RecruitingNCT05890599YoFaPoCoUpdated Jul 10, 2025

Yoga Versus Health Education for the Treatment of Persistent Fatigue in Patients With Post COVID-19 Syndrome

An interventional study of Yoga Therapy and Health Education in Post-COVID-19 Syndrome and Fatigue Post Viral, sponsored by University Hospital Tuebingen. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-07-10.

Sponsored by University Hospital Tuebingen · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany — 14 open to participants now, 17 under way, 2 of them phase 3. Post-Acute COVID-19 Syndrome · Germany.

Planned enrollment
16th of 28
100 · median 108
Started
2023
with 9 others
No phase
20 of 41
7 open now
Primary completion
2025-12
later than 3 of 16 live
Registered
20th of 41
by date
Lead sponsor
2 of 41
University Hospital Tuebingen

Among the 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany, this one is the 16th largest by planned enrollment of the 28 interventional ones that give a count, is one of 10 that started in 2023, is one of 20 with no phase, reaches primary completion later than 3 of the 16 other live ones, and was the 20th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

14 of the 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany, or all of them as a file.
02

Study summary

Evaluation of the short- and medium-term effect of a yoga intervention in addition to routine care compared to health education in addition to routine care on fatigue in patients with post covid syndrome.

03

Conditions studied

  • Post-COVID-19 Syndrome
  • Fatigue Post Viral

Keywords

  • Fatigue
  • Covid
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed COVID-19 diagnosis
  • Follow-up symptoms of ≥ 12 weeks
  • Persistent fatigue (scores ≥4 on the binomial Chalder Fatigue Scale).
  • Self-assessment that fatigue was a consequence of COVID-19 disease
  • Age 18-65 years

Exclusion criteria

Exclusion Criteria:

  • Chronic medical conditions or regular use of medications associated with fatigue
  • Indication of health cause of fatigue other than post-COVID.
  • Indication of other factors as the main cause of fatigue
  • Physical limitations that do not allow participation in the yoga intervention
  • Pregnancy, breastfeeding
  • Concurrent participation in other clinical trials
  • Current yoga practice
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Yoga Therapy

    12 week yoga program, one weekly session of 90 minutes each, plus 2 times weekly 30 minutes of self practice.

    Behavioral: Yoga Therapy

  • Active comparator
    Health Education

    12 week health education program, one weekly session of 90 minutes each, plus 2 times weekly 30 minutes of self practice.

    Behavioral: Health Education

Interventions

  • BehavioralYoga Therapy

    The range of interventions is based on previous studies on yoga interventions specifically for fatigue patients as well as on recommendations, for example, from the WHO. The yoga therapy includes 3 elements: yoga postures (asanas), breathing techniques (pranayama) and relaxation moments. Emphasis on postures and breathing techniques that are considered to be effective for fatigue symptoms, as well as specific breathing exercises to strengthen the respiratory muscles and increase lung volume.

  • BehavioralHealth Education

    Health education courses are conducted on-site once a week for 90 minutes over a 12-week period by a psychologist with clinical experience. The courses are didactic in nature and consist of lectures on topics of interest to patients with post-COVID syndrome and fatigue, followed by questions and discussion sessions. Topics include information on post-COVID syndrome and fatigue, an introduction to self-help for post-viral symptoms, psychosocial problems and fatigue, relaxation and stress management, nutrition, sleep hygiene, exercise, respecting one's own limits, acceptance, finding meaning, and achieving goals.

06

What researchers measure

Primary outcomes

  1. Fatigue

    The chalder fatigue scale is used to assess the severity of fatigue within the last 4 weeks. It contains 11 questions in a four-step answer format (0-4), 7 of which refer to the degree of physical fatigue and 4 to the degree of mental fatigue. In its binomial evaluation (range 0-11) it can be used with a cut-off of (≥ 4) to divide patients into those with and those without fatigue.

    Time frame: 12 weeks

Secondary outcomes

  1. Fatigue

    The chalder fatigue scale is used to assess the severity of fatigue within the last 4 weeks. It contains 11 questions in a four-step answer format (0-4), 7 of which refer to the degree of physical fatigue and 4 to the degree of mental fatigue. In its binomial evaluation (range 0-11) it can be used with a cut-off of (≥ 4) to divide patients into those with and those without fatigue.

    Time frame: 24 weeks

  2. Health related quality of life SF-12

    Short Form 12 Health Survey Questionnaire, The SF-12 represents the most commonly used instrument in clinical trials to assess generic quality of life. The questionnaire captures 8 different subscales, which are combined into a physical and a psychological summated scale.

    Time frame: 12 weeks

  3. Health related quality of life SF-12

    Short Form 12 Health Survey Questionnaire, The SF-12 represents the most commonly used instrument in clinical trials to assess generic quality of life. The questionnaire captures 8 different subscales, which are combined into a physical and a psychological summated scale.

    Time frame: 24 weeks

  4. Health related quality of life EQ-5D-5L

    The EQ-5D-5L is a self-assessed, health related, quality of life questionnaire. The scale measures quality of life on a 5-component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. In this study, the EQ-5D-5L is used for cost-effectiveness analysis, together with healthcare-related costs.

    Time frame: 12 weeks

  5. Health related quality of life EQ-5D-5L

    The EQ-5D-5L is a self-assessed, health related, quality of life questionnaire. The scale measures quality of life on a 5-component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. In this study, the EQ-5D-5L is used for cost-effectiveness analysis, together with healthcare-related costs.

    Time frame: 24 weeks

  6. Psychological symptoms

    The Hospital Anxiety and Depression Scale asks 14 questions, of which 7 are about anxiety and 7 about depression in patients with physical illnesses and physical complaints. More precisely, it measures the self-assessed severity of patients' anxious and depressive symptoms in relation to the past week.

    Time frame: 12 weeks

  7. Psychological symptoms

    The Hospital Anxiety and Depression Scale asks 14 questions, of which 7 are about anxiety and 7 about depression in patients with physical illnesses and physical complaints. More precisely, it measures the self-assessed severity of patients' anxious and depressive symptoms in relation to the past week.

    Time frame: 24 weeks

  8. Sleep quality

    The Pittsburgh Sleep Quality Index (PSQI) assesses the quality of sleep over the past 4 weeks using 24 questions, 17 for self-assessment and 7 for external assessment. It is used clinically to monitor patients with sleep disorders and to screen for sleep disorders in epidemiological studies. In this study, only the 17 self-assessment items are collected.

    Time frame: 12 weeks

  9. Sleep quality

    The Pittsburgh Sleep Quality Index (PSQI) assesses the quality of sleep over the past 4 weeks using 24 questions, 17 for self-assessment and 7 for external assessment. It is used clinically to monitor patients with sleep disorders and to screen for sleep disorders in epidemiological studies. In this study, only the 17 self-assessment items are collected.

    Time frame: 24 weeks

  10. Stress

    The current stress perception of the patients is assessed by means of the Perceived Stress Scale (PSS-10). This measures the current subjective perceived stress of the patients on the basis of 10 items.

    Time frame: 12 weeks

  11. Stress

    The current stress perception of the patients is assessed by means of the Perceived Stress Scale (PSS-10). This measures the current subjective perceived stress of the patients on the basis of 10 items.

    Time frame: 24 weeks

  12. Post-exertional malaise

    Post-exertional malaise (PEM) is a delayed worsening of symptoms that occurs after minimal physical or mental activity. The DePaul-Symptom Questionaire (DSQ) is used to asses PEM.

    Time frame: 12 weeks

  13. Post-exertional malaise

    Post-exertional malaise (PEM) is a delayed worsening of symptoms that occurs after minimal physical or mental activity. The DePaul-Symptom Questionaire (DSQ) is used to asses PEM.

    Time frame: 24 weeks

  14. Body awareness

    The Body Awareness Questionnaire (BAQ) assesses participants' subjective body awareness in four subdimensions: note responses or changes in body processes, predict bodily reaction, sleep-wake cycle, and onset of illness. The validated single-factor German version consists of 17 questions on a 7-point Likert scale from 1 (not at all true about me) to 7 (very true about me). The values of the individual items are added together to form a total score. Body awareness will be used in mediation analyses of treatment effects.

    Time frame: 12 weeks

  15. Body awareness

    The Body Awareness Questionnaire (BAQ) assesses participants' subjective body awareness in four subdimensions: note responses or changes in body processes, predict bodily reaction, sleep-wake cycle, and onset of illness. The validated single-factor German version consists of 17 questions on a 7-point Likert scale from 1 (not at all true about me) to 7 (very true about me). The values of the individual items are added together to form a total score. Body awareness will be used in mediation analyses of treatment effects.

    Time frame: 24 weeks

  16. Self-Efficacy

    The Arthritis Self-Efficacy Scale (ASES) was originally developed in 1989 as part of the Stanford Arthritis Self-Management Study to assess self-efficacy in arthritis patients and has since been used to assess it in many disease conditions. A short version (ASES-8/ASES-D) has been validated. This version surveys in scale level 1-10 the perceived ability to deal with occurring symptoms such as: Pain or fatigue. Self-efficacy will be used in mediation analyses of treatment effects.

    Time frame: 12 weeks

  17. Self-Efficacy

    The Arthritis Self-Efficacy Scale (ASES) was originally developed in 1989 as part of the Stanford Arthritis Self-Management Study to assess self-efficacy in arthritis patients and has since been used to assess it in many disease conditions. A short version (ASES-8/ASES-D) has been validated. This version surveys in scale level 1-10 the perceived ability to deal with occurring symptoms such as: Pain or fatigue. Self-efficacy will be used in mediation analyses of treatment effects.

    Time frame: 24 weeks

  18. Adverse events

    Adverse events and serious adverse events are documented. Adverse events include any adverse symptoms, illnesses, disorders, or accidents that occur during the course of the study. Serious adverse events include events occurring during the course of the study that are immediately life-threatening and/or result in serious health problems (specifically, requiring unanticipated hospitalization or prolongation of hospitalization, or resulting in serious disability or incapacitation). Adverse events (including PEM) and serious adverse events will be documented by participants on a weekly basis throughout the intervention period. Participants will be instructed to immediately notify the study site upon the occurrence of any serious adverse event. The severity as well as the possible causal relationship with the intervention will be assessed by the study physician.

    Time frame: Week 0, 1-12, 13 and 25

  19. C-reactive proteine

    CRP as marker of pro-inflammatory cytokine activity, from blood samples.

    Time frame: 12 weeks

  20. C-reactive proteine

    CRP as marker of pro-inflammatory cytokine activity, from blood samples.

    Time frame: 24 weeks

  21. Interleukine-6

    IL-6, as marker of pro-inflammatory cytokine activity, from blood samples.

    Time frame: 12 weeks

  22. Interleukine-6

    IL-6, as marker of pro-inflammatory cytokine activity, from blood samples.

    Time frame: 24 weeks

  23. D-dimer

    D-dimer, as a by-product of the blood clotting and break-down process that can be measured via analysis of a blood sample

    Time frame: 12 weeks

  24. D-dimer

    D-dimer, as a by-product of the blood clotting and break-down process that can be measured via analysis of a blood sample

    Time frame: 24 weeks

  25. Lactate dehydrogenase

    Lactate dehydrogenase (LDH), measuring the amount of LDH in the blood. Lactate dehydrogenase is an enzyme that the body uses during the process of turning sugar into energy for your cells to use.

    Time frame: 12 weeks

  26. Lactate dehydrogenase

    Lactate dehydrogenase (LDH), measuring the amount of LDH in the blood. Lactate dehydrogenase is an enzyme that the body uses during the process of turning sugar into energy for your cells to use.

    Time frame: 24 weeks

  27. Leukocytes and lymphocytes

    Leukocytes and lymphocytes, from blood samples.

    Time frame: 12 weeks

  28. Leukocytes and lymphocytes

    Leukocytes and lymphocytes, from blood samples.

    Time frame: 24 weeks

  29. Hand grip strength

    Repeated measurement of hand strength can help detect physical decline and inflammatory processes Hand grip strength measurement can be an invaluable tool for monitoring physical performance decline.

    Time frame: 12 weeks

  30. Hand grip strength

    Repeated measurement of hand grip strength can help detect physical decline and inflammatory processes Hand strength measurement can be an invaluable tool for monitoring physical performance decline.

    Time frame: 24 weeks

  31. Movement tracking

    General tracking of patients' movement habits via activity monitor

    Time frame: 12 weeks

  32. Movement tracking

    General tracking of patients' movement habits via activity monitor

    Time frame: 24 weeks

  33. Heart rate variability

    24-hour measurement of heart rate variability (HRV) to determine the functionality of the participant's autonomic nervous system. A 3-channel ECG recorder (SRA/Multi-ECG recorder, SR-Medizinelektronik, Stuttgart, Germany) is used. Several HRV time-domain and HRV frequency-domain measures will be evaluated and analyzed for the total day and night (sleeping time) period as well as for 5-minutes-intervals within these two periods (SDNN, RMSSD, pNN50, SDANN, SDNNI, VLF power, LF power, HF power, LF/HF).

    Time frame: 12 weeks

  34. Heart rate variability

    24-hour measurement of heart rate variability (HRV) to determine the functionality of the participant's autonomic nervous system. A 3-channel ECG recorder (SRA/Multi-ECG recorder, SR-Medizinelektronik, Stuttgart, Germany) is used. Several HRV time-domain and HRV frequency-domain measures will be evaluated and analyzed for the total day and night (sleeping time) period as well as for 5-minutes-intervals within these two periods (SDNN, RMSSD, pNN50, SDANN, SDNNI, VLF power, LF power, HF power, LF/HF).

    Time frame: 24 weeks

  35. Cost for Patient Questionnaire (CoPaQ)

    Direct medical and non-medical costs are collected using this questionnaire. The questionnaire is a modified version of the Cost for Patient Questionnaire (CoPaQ), designed to collect all information on health care costs.

    Time frame: 12 weeks, 24 weeks

Other outcomes

  1. Therapy rationale and therapy expectancy

    The Credibility Expectancy Questionnaire (CEQ) published by Ametrano, et al. 2011 and validated as German version by Rieke, et al. 2013 is used to measure Therapierationale and Therapieerwartung at baseline. It measures these over 6 items using 9-point Likert scales.

    Time frame: Week 0

  2. Personality dimensions

    Big-Five-Inventory-10 (BFI-10) is used to assess personality dimensions based on the big-5 model.

    Time frame: Week 0

  3. Qualitative Interviews

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
  • Bosch-Health-Campus
    Stuttgart, 70376, Germany
    Recruiting
08

References and documents

Publications

  • Cramer H, Morchen L, Vagedes J, Klenk J, Jager S, Schleinzer A, Anheyer D, Bilc M, Schroter M, Kessler C, Jeitler M. Yoga versus health education for persistent fatigue in patients with post-COVID-19 syndrome: protocol for a multicentre randomised controlled trial. BMJ Open. 2025 Oct 23;15(10):e107840. doi: 10.1136/bmjopen-2025-107840. PubMed 41130694 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Dec 2025, 30 months after the start.

Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 30 months is above that.

Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2023
First posted
Jun 6, 2023
StartActual
Jun 10, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Mar 31, 2026
Last update
Jul 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05890599
Collaborators
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF), Charite University, Berlin, Germany
Responsible party
Sponsor
First posted
Jun 6, 2023
Start date
Jun 10, 2023
Primary completion
Dec 31, 2025 (estimated)
Completion
Mar 31, 2026 (estimated)
Last update
Jul 10, 2025

Study contacts

Holger Cramer, Professor
Contact
yasemin.anguelov@bosch-health-campus.com
+49 711 8101 7858
Holger Cramer, Professor
study director · University Hospital Tübingen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion